

TAOS HEALTH SYSTEMS, INC.
CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED MAY 31, 2024 AND 2023



CPAs | CONSULTANTS | WEALTH ADVISORS

[CLAconnect.com](https://www.CLAconnect.com)

**TAOS HEALTH SYSTEMS, INC.
TABLE OF CONTENTS
YEARS ENDED MAY 31, 2024 AND 2023**

| | |
|--|-----------|
| INDEPENDENT AUDITORS' REPORT | 1 |
| CONSOLIDATED FINANCIAL STATEMENTS | |
| CONSOLIDATED BALANCE SHEETS | 4 |
| CONSOLIDATED STATEMENTS OF OPERATIONS | 6 |
| CONSOLIDATED STATEMENTS OF NET ASSETS | 7 |
| CONSOLIDATED STATEMENTS OF CASH FLOWS | 8 |
| NOTES TO CONSOLIDATED FINANCIAL STATEMENTS | 9 |
| INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH <i>GOVERNMENT AUDITING STANDARDS</i> | 29 |
| INDEPENDENT AUDITORS' REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM, REPORT ON INTERNAL CONTROL OVER COMPLIANCE, AND REPORT ON THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY UNIFORM GUIDANCE | 31 |
| SCHEDULE OF FINDINGS AND QUESTIONED COSTS | 34 |
| SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS | 37 |
| NOTE TO SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS | 38 |



INDEPENDENT AUDITORS' REPORT

Board of Directors
Taos Health Systems, Inc.
Taos, New Mexico

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of Taos Health Systems, Inc. (the Organization), which comprise the consolidated balance sheets as of May 31, 2024 and 2023, and the related consolidated statements of operations, net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Organization as of May 31, 2024 and 2023, and the results of their operations, changes in their net assets, and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for one year after the date the consolidated financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and the *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards, as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards, is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 30, 2024 on our consideration of the Organization's internal control over financial reporting and on our tests of compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion of the effectiveness of the Organization's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Organization's internal control over financial reporting and compliance.



CliftonLarsonAllen LLP

Denver, Colorado
October 30, 2024

TAOS HEALTH SYSTEMS, INC.
CONSOLIDATED BALANCE SHEETS
MAY 31, 2024 AND 2023

| | 2024 | 2023 |
|--|---------------|---------------|
| ASSETS | | |
| CURRENT ASSETS | | |
| Cash and Cash Equivalents | \$ 13,652,204 | \$ 11,837,732 |
| Restricted Cash | 1,454,114 | - |
| Short-Term Investments | 30,902 | 29,865 |
| Patient Accounts Receivable | 7,955,237 | 7,042,299 |
| Estimated Amounts Due from Third-Party Payors | 462,645 | 1,569,086 |
| Other Receivables | 676,360 | 343,202 |
| Inventory Supplies | 997,481 | 1,629,357 |
| Prepaid Expenses and Other | 1,394,308 | 1,305,798 |
| Total Current Assets | 26,623,251 | 23,757,339 |
| ASSETS LIMITED AS TO USE - BOARD-DESIGNATED | 94,955 | 88,989 |
| PROPERTY AND EQUIPMENT, NET | 12,748,059 | 14,185,934 |
| RIGHT-OF-USE ASSETS, NET - OPERATING | 2,860,648 | 1,672,583 |
| GOODWILL, NET | 132,168 | 153,369 |
| Total Assets | \$ 42,459,081 | \$ 39,858,214 |

See accompanying Notes to Consolidated Financial Statements.

TAOS HEALTH SYSTEMS, INC.
CONSOLIDATED BALANCE SHEETS (CONTINUED)
MAY 31, 2024 AND 2023

| | 2024 | 2023 |
|---|---------------|---------------|
| LIABILITIES AND NET ASSETS | | |
| CURRENT LIABILITIES | | |
| Accounts Payable | \$ 7,861,455 | \$ 7,771,594 |
| Accrued Expenses | 2,585,396 | 2,268,762 |
| Current Portion of Finance Lease Obligations | - | 374 |
| Current Portion of Operating Lease Obligations | 651,193 | 450,578 |
| Deferred Revenue | 41,536 | 41,536 |
| Total Current Liabilities | 11,139,580 | 10,532,844 |
| LONG-TERM LIABILITIES | | |
| Operating Lease Obligations, Less Current Portion | 2,218,591 | 1,222,005 |
| Total Long-Term Liabilities | 2,218,591 | 1,222,005 |
| Total Liabilities | 13,358,171 | 11,754,849 |
| NET ASSETS | | |
| Net Assets Without Donor Restrictions | 27,234,881 | 27,669,227 |
| Net Assets With Donor Restrictions | 1,866,029 | 434,138 |
| Total Net Assets | 29,100,910 | 28,103,365 |
| Total Liabilities and Net Assets | \$ 42,459,081 | \$ 39,858,214 |

See accompanying Notes to Consolidated Financial Statements.

TAOS HEALTH SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED MAY 31, 2024 AND 2023

| | 2024 | 2023 |
|---|---------------|---------------|
| OPERATING REVENUE | | |
| Patient Service Revenue | \$ 73,982,749 | \$ 69,950,074 |
| Other Operating Revenue | 7,868,249 | 10,340,475 |
| Net Assets Released from Restrictions Used for Operations | 183,024 | 125,221 |
| Total Operating Revenue | 82,034,022 | 80,415,770 |
| OPERATING EXPENSES | | |
| Salaries and Wages | 34,630,731 | 31,664,815 |
| Purchased Services | 15,036,563 | 18,854,734 |
| Supplies and Minor Equipment | 13,266,959 | 12,012,724 |
| Payroll Taxes and Benefits | 7,323,840 | 6,495,644 |
| Professional Fees | 3,110,910 | 3,103,629 |
| Depreciation and Amortization | 1,863,163 | 2,081,962 |
| Leases and Rentals | 1,308,914 | 1,416,101 |
| Repairs and Maintenance | 1,643,248 | 1,382,685 |
| Other | 5,325,954 | 4,518,353 |
| Insurance | 2,657,905 | 2,165,731 |
| Telephone and Utilities | 597,085 | 664,651 |
| Travel, Meals, and Entertainment | 106,183 | 145,500 |
| Interest | 45,846 | 43,269 |
| Total Operating Expenses | 86,917,301 | 84,549,798 |
| LOSS FROM OPERATIONS | (4,883,279) | (4,134,028) |
| NONOPERATING GAINS (LOSSES) | | |
| Investment Income | 63,720 | 39,718 |
| Tax Revenues | 4,399,928 | 4,564,518 |
| Other Income (Loss) | (14,715) | 15,926 |
| Net Nonoperating Gains | 4,448,933 | 4,620,162 |
| INCREASE (DECREASE) IN NET ASSETS WITHOUT DONOR RESTRICTIONS | \$ (434,346) | \$ 486,134 |

See accompanying Notes to Consolidated Financial Statements.

TAOS HEALTH SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF NET ASSETS
YEARS ENDED MAY 31, 2024 AND 2023

| | 2024 | 2023 |
|--|---------------|---------------|
| NET ASSETS WITHOUT DONOR RESTRICTIONS | | |
| Increase (Decrease) in Net Assets Without Donor Restrictions | \$ (434,346) | \$ 486,134 |
| NET ASSETS WITH DONOR RESTRICTIONS | | |
| Restricted Grants and Donations | 1,614,915 | 205,539 |
| Net Assets Released from Restrictions | (183,024) | (125,221) |
| Increase in Net Assets with Donor Restrictions | 1,431,891 | 80,318 |
| INCREASE IN NET ASSETS | 997,545 | 566,452 |
| Net Assets - Beginning of Year | 28,103,365 | 27,536,913 |
| NET ASSETS - END OF YEAR | \$ 29,100,910 | \$ 28,103,365 |

See accompanying Notes to Consolidated Financial Statements.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

| | 2024 | 2023 |
|--|---------------|---------------|
| CASH FLOWS FROM OPERATING ACTIVITIES | | |
| Increase in Net Assets | \$ 997,545 | \$ 566,452 |
| Adjustment to Reconcile Increase in Net Assets to Net Cash Provided (Used) by Operating Activities: | | |
| Depreciation and Amortization | 1,863,163 | 2,081,962 |
| Loss on Disposal of Property and Equipment | 30,590 | - |
| Net Unrealized (Gains) Losses on Assets Limited as to use | (2,856) | 6,076 |
| Loss on Equity Method Investment | - | 15,218 |
| Noncash Lease Expense | 9,136 | - |
| Change in Current Assets and Liabilities: | | |
| Patient Accounts Receivable | (912,938) | 3,156,369 |
| Other Receivables | (333,158) | 97,486 |
| Inventory Supplies | 631,876 | 44,778 |
| Prepaid Expenses and Other | (88,510) | (328,517) |
| Accounts Payable | 89,861 | (1,227,892) |
| Accrued Expenses | 316,634 | (111,258) |
| Net Amounts Due from Third-Party Payors | 1,106,441 | (1,915,060) |
| Deferred Revenue | - | (3,448,329) |
| Net Cash Provided (Used) by Operating Activities | 3,707,784 | (1,062,715) |
| CASH FLOWS FROM INVESTING ACTIVITIES | | |
| Purchase of Property and Equipment | (434,677) | (1,990,372) |
| Net Purchases of Assets Limited as to Use | (4,147) | (5,247) |
| Net Cash Used by Investing Activities | (438,824) | (1,995,619) |
| CASH FLOWS FROM FINANCING ACTIVITIES | | |
| Principal Payments Under Finance Lease Obligations | (374) | (84,647) |
| Net Cash Used by Financing Activities | (374) | (84,647) |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 3,268,586 | (3,142,981) |
| Cash, Cash Equivalents, and Restricted Cash - Beginning of Year | 11,837,732 | 14,980,713 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH - END OF YEAR | \$ 15,106,318 | \$ 11,837,732 |
| RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | | |
| Cash and Cash Equivalents | \$ 13,652,204 | \$ 11,837,732 |
| Restricted Cash | 1,454,114 | - |
| Total Cash, Cash Equivalents, and Restricted Cash | \$ 15,106,318 | \$ 11,837,732 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | | |
| Cash Payments For Interest | \$ 45,846 | \$ 43,269 |
| Assets Acquired through Lease Arrangements | \$ 1,771,459 | \$ - |

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

Taos Health Systems, Inc. (the Organization), located in Taos, New Mexico, is a nonprofit critical access hospital along with specialty clinics as further described below. The Organization provides inpatient, outpatient, emergency care, and clinical services for residents of Taos County and surrounding areas. The consolidated financial statements of the Organization include Holy Cross Hospital (the Hospital) and Taos Professional Services (TPS).

TPS, formed in 2008, is currently comprised of the following distinct clinical units:

- Holy Cross Women's Health Institute (WHI), which provides obstetrics and gynecology services.
- Taos Surgical Specialties (TSS), which provides surgical services including cardiology.
- Holy Cross Pediatrics and Primary Care, provides basic family clinic services.
- Taos Clinic for Children and Youth, provides basic pediatric clinic services.

Basis of Accounting

The consolidated financial statements of the Organization have been prepared on the accrual basis, whereas, revenue is recognized when earned, and expenses are recognized when incurred, which is in accordance with accounting principles generally accepted in the United States of America.

Principles of Consolidation

The consolidated financial statements include the accounts of the Hospital and TPS. All material intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Basis of Presentation

Net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the net assets of the Organization and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions – Include net assets available for use in general operations and not subject to donor (or certain grantor) restrictions. At times, the governing board can designate, from net assets without donor restrictions, net assets for a board-designated endowment or other purposes. At May 31, 2024 and 2023, the board of directors has designated assets to be used for the First Steps Program.

Net Assets With Donor Restrictions – Include net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. At May 31, 2024 and 2023, no donor-imposed restrictions were perpetual in nature. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource has been fulfilled, or both.

Revenues are reported as increases in net assets without donor restrictions, unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions, unless their use is restricted by explicit donor restriction or by law. Expirations of donor restrictions on assets are reported as transfers between the applicable classes of net assets. Contributions with externally imposed restrictions that are met in the same year as received are reported as revenues of the net asset without donor restriction class.

Cash and Cash Equivalents

Cash and cash equivalents primarily consist of demand deposit and money market accounts. For purposes of reporting cash flows, cash includes cash on hand and cash in banks. The Organization has from time to time deposits in excess of Federal Depository Insurance Corporation limits. Management believes any credit risk related to these deposits is minimal.

Restricted Cash

Restricted cash consists of a donation received that has yet to be spent for the purpose of the donation.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Investments and Investment Income

Investments in equity securities with readily determinable fair values and all debt securities included in investment portfolios are measured at fair value, based on quoted market prices.

Investment return that is initially restricted by donor stipulation and for which the restriction will be satisfied in the same year is included in net assets without donor restrictions. Restricted investment income where the restriction is not satisfied in the same year is reflected in the consolidated statements of net assets as with donor restrictions based upon the existence and nature of any donor or legally imposed restrictions.

Patient Accounts Receivable

Patient accounts receivable are recorded in the accompanying consolidated balance sheets at the estimated transaction price based on certain assumptions. In evaluating the collectability of patient accounts receivable, the Organization analyzes its past history and identifies trends for each of its major payor sources of revenue to estimate the transaction price. Management regularly reviews data about these major payor sources of revenue in evaluating the sufficiency of the allowance for implicit price concessions. For receivables associated with services provided to patients who have third party coverage, the transaction price is based on the estimated explicit price concessions, which is based on current contract prices or historical claims paid data by payor. For uninsured patients (which includes both patients without insurance and patients with deductible and copayment balances due which third party coverage exists for a portion of the bill), the estimated transaction price is determined using estimates of historical collection experience. These estimates are adjusted for recoveries and any anticipated changes in trends, including significant changes in payor mix, economic conditions or trends in federal and state governmental health care coverage.

Management believes the composition of receivables at year-end is consistent with historical conditions as credit terms and practices and the customer base has not changed significantly; therefore, the Organization has maintained consistent methodology in estimation of credit losses. Management has determined the estimate of expected credit losses is not material to the consolidated financial statements.

Inventory Supplies

Inventory supplies are valued at the lower of cost (first-in, first-out method) or net realizable value.

Assets Limited as to Use

Assets limited as to use primarily include designated assets set aside by the board of directors (the Board) for the First Steps Program, over which the Board retains control and may at its discretion subsequently use for other purposes.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Property and Equipment, Net

Property and equipment acquisitions are recorded at cost. The Organization capitalizes property and equipment additions in excess of \$5,000. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed using the straight-line method. Equipment under finance lease obligations is amortized on the straight-line method over the shorter period of the lease term or the estimated useful life of the equipment. Such amortization is included in depreciation expense in the consolidated statements of operations. Depreciation and amortization expense for fiscal years 2024 and 2023 was \$1,841,962 and \$2,060,761, respectively.

The estimated useful lives for each major depreciable classification of property and equipment are as follows:

| | |
|----------------------------|---------------|
| Buildings and Improvements | 3 to 40 Years |
| Equipment | 3 to 10 Years |

Impairment of Long-Lived Assets

The Organization reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may be not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of carrying amount or the fair value less costs to sell. There was no impairment of long-lived assets at May 31, 2024 and 2023.

Leases

The Organization determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets – operating and lease liability – operating, and finance leases are included in ROU assets – financing and lease liability – financing in the consolidated financial statements.

ROU assets represent the Organization's right to use an underlying asset for the lease term and lease liabilities represent the Organization's obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Organization will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. The Organization has elected to recognize payments for short-term leases with a lease term of 12 months or less as expense as incurred and these leases are not included as lease liabilities or right of use assets on the consolidated balance sheets.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Leases (Continued)

The individual lease contracts do not provide information about the discount rate implicit in the lease. Therefore, the Organization has elected to use a risk-free discount rate determined using a period comparable with that of the lease term for computing the present value of lease liabilities.

Equity Method Investment

The Organization had a 50% ownership in Taos Community Health Plan, Inc., a Physician Hospital Organization (PHO) created to present a united group of health care providers to negotiate contracts with managed care organizations. This investment was accounted for under the equity method of accounting. Under the equity method, the original investment was recorded at cost and adjusted by the Organization's share of undistributed earnings or losses of the PHO. The PHO was dissolved in fiscal year 2023.

Goodwill, Net

In May 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-06, *Extending the Private Company Accounting Alternatives on Goodwill and Certain Identifiable Intangible Assets to Not-for-Profit Entities*. The core principal of the new guidance is that not-for-profit entities have a one-time unconditional option to forgo a preferability assessment the first time they elect a not-for-profit accounting alternative within the scope of ASU 2019-06.

The Organization adopted ASU 2019-06 while simultaneously adopting FASB 2014-02, *Intangibles-Goodwill and Other (Topic 350): Accounting for Goodwill*, effective June 1, 2020.

Goodwill relates to the acquisition of a physician clinic by the Organization and represents the excess of the purchase price of the acquired business over the fair value of the assets acquired and liabilities assumed. Goodwill is reviewed for potential impairment if a triggering event occurs that indicates the Organization's fair value may be below its carrying value. Measurement of goodwill impairment is based on the excess of the carrying value, including goodwill, over the fair value. At May 31, 2024 and 2023, the Organization has determined that there is no impairment of goodwill.

Amortization expense related to goodwill was \$21,201 for the years ending May 31, 2024 and 2023.

The future annual amortization expense for goodwill subject to amortization is as follows:

| <u>Year Ending May 31,</u> | <u>Amount</u> |
|----------------------------|--------------------------|
| 2025 | \$ 21,201 |
| 2026 | 21,201 |
| 2027 | 21,201 |
| 2028 | 21,201 |
| 2029 | 21,201 |
| Thereafter | 26,163 |
| Total | <u><u>\$ 132,168</u></u> |

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Deferred Revenue

Revenue received in advance of the performance of services deemed to be exchange transactions are deferred until such time as related expenditures are incurred and then revenue is recognized.

Performance Indicator

Increase (decrease) in net assets without donor restrictions, as reflected in the accompanying consolidated statements of operations, is the performance indicator. The performance indicator includes all changes in net assets without donor restrictions, including investment income not restricted by donors and tax revenues.

Patient Service Revenue

The Organization has agreements with third-party payors that provide for payments to the Organization at amounts different from its established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Patient service revenue is reported at the estimated transaction price from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments under reimbursement agreements with third-party payors. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods, as final settlements are determined.

Charity Care

The Organization provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its established rates. Because the Organization does not pursue collection of amounts determined to qualify as charity care, they are not reported as patient service revenue. The Organization's direct and indirect costs for services furnished under its charity care policy aggregated approximately \$651,000 and \$80,000 in 2024 and 2023, respectively.

Contributions

Contributions without donor restrictions are included in other operating revenue. Contributions restricted by the donors for specific purposes are reported as net assets with donor restrictions. As donor-restricted funds are used for operating expenses, such funds are transferred to net assets without donor restrictions and reported in the consolidated statements of operations.

Tax Revenues

In November 2020, the voters of Taos County, New Mexico passed a levy of one mill for funding infrastructure maintenance and improvements for Holy Cross Hospital. The mill is effective for the 2021 tax year for a period of four years. The taxes are reported as revenue in the year in which the funds are approved to be spent. During the year ended May 31, 2024 and 2023, the Organization recorded \$1,730,606 and \$2,513,186, respectively, in revenue from the mill levy which is included in tax revenues on the consolidated statements of operations.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Tax Revenues (Continued)

In March 2020, the Taos County Board of Commissioners approved a gross receipts tax increase to support operations of the Organization. During the years ended May 31, 2024 and 2023, the Organization recorded \$2,521,405 and \$2,051,332, respectively in revenue from the gross receipts tax which is included in tax revenues on the consolidated statements of operations.

Advertising Costs

The Organization expenses advertising costs as incurred. Advertising expenses for the years ended May 31, 2024 and 2023 were \$113,291 and \$84,141 respectively.

Professional Liability Claims

The Organization recognizes an accrual for claim liabilities based on estimated ultimate losses and costs of associated with settling claims and a receivable to reflect the estimated insurance recoveries, if any.

Fair Value of Financial Instruments

The Organization adopted accounting standards regarding the fair value measurement of financial assets and liabilities. Fair value measurement applies to reported balances that are required or permitted to be measured at fair value under an existing accounting standard. The Organization emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability and establishes a fair value hierarchy.

The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:

Level 1 – Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Organization has the ability to access.

Level 2 – Inputs that include quoted prices for similar assets and liabilities in active markets and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Fair values for these instruments are estimated using pricing models, quoted prices of securities with similar characteristics, or discounted cash flows.

Level 3 – Inputs that are unobservable inputs for the asset or liability, which are typically based on an entity's own assumptions, as there is little, if any, related market activity.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Fair Value of Financial Instruments (Continued)

Investments are recorded at fair value on a recurring basis. Fair value measurement is based upon quoted prices, if available. If quoted prices are not available, fair values are measured using independent pricing models or other model-based valuation techniques such as the present value of future cash flows, adjusted for the security's credit rating, prepayment assumptions, and other factors such as credit loss assumptions.

Adoption of New Accounting Standard

The Organization adopted ASU 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*, as amended, which modifies the measurement of expected credit losses. The Organization adopted this new guidance utilizing the modified retrospective transition method. The adoption of this standard did not have a material impact on the Organization's consolidated financial statements, but did change how the allowance for credit losses is determined.

Tax Status

The IRS has determined that the Organization is a tax-exempt, nonprofit corporation under Section 501(c)(3) of the Internal Revenue Code (IRC).

The Organization follows the guidance in the accounting standards regarding the recognition and measurement of uncertain tax positions. The guidance clarifies the accounting for uncertainty in income taxes recognized in an entity's financial statements. The guidance further prescribes recognition and measurement of tax provisions taken or expected to be taken on a tax return that are not certain to be realized. The application of this standard has no impact on the Organization's consolidated financial statements.

The Organization's income tax returns are subject to review and examination by federal, state, and local authorities.

Subsequent Events

In preparing the consolidated financial statements, the Organization has considered events and transactions that have occurred through October 30, 2024, the date in which the consolidated financial statements were available to be issued.

NOTE 2 PATIENT SERVICE REVENUE

Patient service revenue is reported at the amount that reflects the consideration to which the Organization expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Organization bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 2 PATIENT SERVICE REVENUE (CONTINUED)

Performance obligations are determined based on the nature of the services provided. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. The Organization believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care services or patients receiving services in outpatient clinics.

The opening and closing contract balances were as follows:

| | Patient Receivables |
|----------------------------|------------------------|
| Balance as of June 1, 2022 | \$ 10,198,668 |
| Balance as of May 31, 2023 | 7,042,299 |
| Balance as of May 31, 2024 | 7,955,237 |

The Organization measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Organization does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Organization has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Organization uses a portfolio approach to account for categories of patient contracts as a collective group, rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes for inpatient revenue and outpatient revenue. Based on the historical collection trends and other analysis, the Organization believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

The Organization determines the transaction price based on standard charges for goods and services provided, reduced by explicit price concessions provided to third-party payors, discounts provided to uninsured patients in accordance with the Organization's policy, and/or implicit price concessions provided to uninsured patients. Estimated explicit price concessions and discounts are based on contractual agreements, its discount policy (or policies), and historical experience. Estimated implicit price concessions are based on its historical collection experience with this class of patients.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 2 PATIENT SERVICE REVENUE (CONTINUED)

The Organization has agreements with third-party payors that provide for payments to the Organization at amounts different from its established rates. A summary of the payment arrangements with major third-party payors is as follows:

Medicare

The Organization has critical access hospital status and is reimbursed by Medicare for inpatient and outpatient services on a cost basis as defined and limited by the Medicare program. The Medicare program's administrative procedures preclude final determination of amounts due to the Organization for such services until three years after the Organization's cost reports are audited or otherwise reviewed and settled upon by the Medicare intermediary.

The Organization's Medicare cost reports have been finalized by the Medicare fiscal intermediary through the year ended May 31, 2022. The Organization's classification of patients under the Medicare program and the appropriateness of their admission are subject to an independent review by the peer review organization under contract with the Organization.

Medicaid

Inpatient acute care services rendered to Medicaid program beneficiaries are paid at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Outpatient services and defined capital are paid based on a percentage above the state determined fee schedule. Cost reports are required; however, cost report settlements have been discontinued.

Other Third-Party Payors

The Organization has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment to the Organization under these agreements includes prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Self-Pay Patients

The Organization recognizes patient service revenue associated with services provided to patients who have third-party payor coverage on the basis of contractual rates for the services rendered. For uninsured patients that do not qualify for charity care, the Organization recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a significant portion of the Organization's uninsured patients will be unable or unwilling to pay for the services provided. Thus, the Organization records a significant provision for uncollectible accounts related to uninsured patients in the period the services are provided.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 2 PATIENT SERVICE REVENUE (CONTINUED)

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Organization's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Organization. In addition, the contracts the Organization has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Organization also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Organization estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Additional revenue recognized due to the changes in its estimates of implicit price concessions, discounts, and contractual adjustments were not considered material for the years ended May 31, 2024 and 2023.

The Organization provides care to patients regardless of their ability to pay. Therefore, the Organization has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balance (for example, copays, and deductibles). The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amount the Organization expects to collect based on its collection history with those patients.

Patients who meet the Organization's criteria for charity care are provided care without charge. Such amounts determined to qualify as charity care are not reported as revenue.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 2 PATIENT SERVICE REVENUE (CONTINUED)

The Organization has determined the nature, amount, timing and uncertainty of revenue and cash flows are affected by the following factors:

- Payors (for example, Medicare, Medicaid, managed care or other insurance, patient) have different reimbursement/payment methodologies
- Length of patient's service/episode of care
- Geography of the service location
- Method of reimbursement (fee for service or capitation)
- The Organization's line of business that provided the service (for example, hospital inpatient, hospital outpatient, clinic, etc.)

For the years ended May 31, 2024 and 2023, all of the patient revenue recognized by the Organization was from goods and services that transfer to customer over time.

Revenue from the Medicare and Medicaid programs accounted for approximately 48% and 18%, respectively, of the Organization's patient service revenue for the year ended May 31, 2024, and 48% and 20%, respectively, of the Organization's patient service revenue for the year ended May 31, 2023.

Hospital and Targeted Access Payments

In accordance with federal rule 42 CFR 438.60, the Hospital Access Payments (HAP) program is paid through the Centennial Care Managed Care Organizations (MCOs); payments are not made directly by HSD. HAP program payments are calculated based on each MCO's member utilization, at each hospital, for both inpatient and outpatient discharges. Each discharge has an additional add-on that is paid based on a calculated formula. The add-on payment amount changes each quarter. Since the HAP is based on actual utilization, there will not be a reconciliation of funds. The Targeted Access Payments (TAP) program was designed to alleviate the discrepancy between the HAP payment and the Uncompensated Care (UC) payment under the former Safety Net Care Pool (SNCP) model. Unlike the HAP program, HSD will make payments under TAP directly to the hospitals quarterly. The TAP is determined by taking the calculated HAP payment and comparing that with the UC payment on a quarterly basis. If the HAP payment is less than the UC payment, HSD will make a TAP payment for the difference.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 3 LIQUIDITY AND AVAILABILITY

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, comprise the following:

| | 2024 | 2023 |
|--|---------------|---------------|
| Financial Assets at Year-End: | | |
| Cash and Cash Equivalents | \$ 13,652,204 | \$ 11,837,732 |
| Short-Term Investments | 30,902 | 29,865 |
| Receivables: | | |
| Patient Accounts Receivable | 7,955,237 | 7,042,299 |
| Estimated Amounts Due from Third-Party Payors | 462,645 | 1,569,086 |
| Other | 676,360 | 343,202 |
| Assets Limited as to Use - Board-Designated | 94,955 | 88,989 |
| Total Financial Assets Available Within One Year | \$ 22,872,303 | \$ 20,911,173 |

The Organization has certain board-designated net assets limited as to use which are available for the First Steps Program and nursing scholarships within one year in the normal course of operations. Accordingly, the assets have been included in the qualitative information above for financial assets to meet general expenditures within one year.

NOTE 4 INVESTMENTS AND INVESTMENT INCOME

Assets Limited as to Use

The composition of assets limited as to use at May 31, 2024 and 2023 are shown in the following table. Assets limited as to use are stated at fair value.

| | 2024 | 2023 |
|--|-----------|-----------|
| Internally Designated For First Step Program | | |
| Cash and Cash Equivalents | \$ 18 | \$ 17 |
| Mutual Funds | 94,937 | 88,972 |
| Total Assets Limited as to Use | \$ 94,955 | \$ 88,989 |

Investment Income

Investment income, fees, and gains and losses on assets limited as to use and cash and cash equivalents consist of the following for the years ended May 31:

| | 2024 | 2023 |
|---|-----------|-----------|
| Interest and Dividend Income, Net | \$ 55,250 | \$ 43,723 |
| Realized and Unrealized Gains (Losses) on Investments, Net | 8,470 | (4,005) |
| Total Investment Income | \$ 63,720 | \$ 39,718 |

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 5 PROPERTY AND EQUIPMENT, NET

A summary of property and equipment at May 31 follows:

| | <u>2024</u> | <u>2023</u> |
|--------------------------------|----------------------|----------------------|
| Land | \$ 2,184,324 | \$ 2,165,031 |
| Leasehold Improvements | 3,387,772 | 3,391,226 |
| Buildings | 13,963,296 | 13,897,958 |
| Equipment | 21,509,957 | 22,920,136 |
| Construction in Progress | 173,678 | 401,814 |
| Total Property and Equipment | <u>41,219,027</u> | <u>42,776,165</u> |
| Less: Accumulated Depreciation | <u>(28,470,968)</u> | <u>(28,590,231)</u> |
| Property and Equipment, Net | <u>\$ 12,748,059</u> | <u>\$ 14,185,934</u> |

Construction in progress as of May 31, 2024, consists of various projects which are expected to be completed in fiscal year 2025. The expected total cost of these projects is approximately \$240,000 and the projects are being funded internally.

NOTE 6 DEFERRED REVENUE

As part of the Organization's response to the COVID-19 pandemic it received advanced payments from Medicare in the amount of \$7,071,126. These payments were received in April 2020 and needed to start to be repaid within a year from receipt. The Organization had up to 29 months from the date the payments were made to repay the balance. Medicare recouped advanced payments in the amount of \$-0- and \$1,966,944 during fiscal years 2024 and 2023, respectively. As of May 31, 2024 and 2023, there was \$-0- remaining of advanced payments to be recouped.

As part of the Organization's response to the COVID-19 pandemic it received payments from the CARES Act Provider Relief Fund (PRF), which is administered by the U.S. Department of Health and Human Services. The Organization recognized PRF revenue in the amount of \$-0- and \$2,204,218 during fiscal years 2024 and 2023, respectively. The revenues recognized are included in other operating revenue on the consolidated statements of operations. The PRF payments have terms and conditions that the Organization is required to follow and these funds are subject to audit. Include in the PRF terms and conditions is a potential for repayment of these funds if they are not fully used in line with the terms and conditions. Management believes the amounts have been recognized appropriately as of May 31, 2024 and 2023.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 7 NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions are available for the following purposes or periods:

| | 2024 | 2023 |
|---|--------------|------------|
| Subject to Expenditure for Specified Purpose: | | |
| Health Education | \$ 36,242 | \$ 33,405 |
| Purchase of Equipment | 1,490,136 | 53,136 |
| Health Care Programs | 339,651 | 347,597 |
| Total | \$ 1,866,029 | \$ 434,138 |

NOTE 8 CONCENTRATIONS OF CREDIT RISK

The Organization grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors at May 31 is as follows:

| | 2024 | 2023 |
|--------------------------|-------|-------|
| Medicare | 38 % | 34 % |
| Medicaid | 19 | 17 |
| Other Third-Party Payors | 24 | 14 |
| Patients | 19 | 35 |
| Total | 100 % | 100 % |

NOTE 9 FAIR VALUE MEASUREMENTS

The Organization uses fair value measurements to record fair value adjustments to certain assets and to determine fair value disclosures. For additional information on how the Organization measures fair value refer to Note 1 – Summary of Significant Accounting Policies.

The following table disclose the by level the fair value hierarchy of the Organization's assets at fair value as of May 31, 2024 and 2023:

| | 2024 | | | |
|---------------------------------------|-----------|-----------|---------|------------|
| | Level 1 | Level 2 | Level 3 | Total |
| Investments: | | | | |
| Mutual Funds | \$ 94,937 | \$ - | \$ - | \$ 94,937 |
| Beneficial Interest in Taos Community | | | | |
| Foundation Investments | - | 30,902 | - | 30,902 |
| Total Investments | \$ 94,937 | \$ 30,902 | \$ - | \$ 125,839 |

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 9 FAIR VALUE MEASUREMENTS (CONTINUED)

| | 2023 | | | Total |
|---|-----------|-----------|---------|------------|
| | Level 1 | Level 2 | Level 3 | |
| Investments: | | | | |
| Mutual Funds | \$ 88,972 | \$ - | \$ - | \$ 88,972 |
| Beneficial Interest in Taos Community Foundation Investments | - | 29,865 | - | 29,865 |
| Total Investments | \$ 88,972 | \$ 29,865 | \$ - | \$ 118,837 |

The Organization has an investment held at the Taos Community Foundation. The investment is a diversified portfolio consisting of various mutual funds. All of the securities are priced on observable inputs. Due to the nature of the valuation inputs, the interest is classified within Level 2 of the hierarchy.

NOTE 10 PENSION PLAN

Under a collective bargaining agreement between the Organization and the Professional Performance Association, affiliated with District 1199 NM, National Union of Hospital and Health Care Employees, AFSCME AFL-CIO, a defined contribution pension plan (the Plan) was established under Section 403(b) of the Internal Revenue Code. The current collective bargaining agreement was renewed on June 1, 2021 through May 31, 2024. Subsequent to year end a new collective bargaining agreement was entered into through August 31, 2027.

Under the agreement as amended, the Organization maintains a qualified, long-term, tax-deferred savings plan. Effective January 1, 2021, for employees earning less than \$35,250 annually, the Organization will match the employee's contribution to the Plan up to \$705 annually. For employees earning more than \$35,250 annually and who contribute at least \$705, the Organization will match the employee's contribution up to 3.0% of the employee's annual compensation, not to exceed \$5,000 annually. Only employees eighteen (18) years of age or older qualify. Members of the Plan will be vested in the Plan on a five-year graduated schedule, but fully vested no later than the employee's sixty-fifth birthday. The Organization appoints a Plan administrator, prepares and distributes summary Plan descriptions, and assists the Plan administrator in distributing reports to individual participants no less frequently than annually. The Organization also pays all direct administrative costs to operate the Plan.

All employees, whether represented by the bargaining unit or not, who meet the eligibility requirements are eligible to participate and receive the contributions as noted above. Pension expense was approximately \$589,000 and \$509,000 for fiscal years 2024 and 2023, respectively.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 11 FUNCTIONAL EXPENSES

The consolidated financial statements report certain expense categories that are attributable to more than health care services or support functions. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. Costs not directly attributable to a function, including depreciation, interest, and other occupancy costs, are allocated to a function based on a square-footage or units-of-service basis. Allocated health care services costs not allocated on a units-of-service basis are otherwise allocated based on revenue. At May 31, expenses related to providing these services are as follows:

| 2024 | Health Care Services | General and Administrative | Total |
|----------------------------------|-------------------------|-------------------------------|----------------------|
| Salaries and Wages | \$ 26,307,770 | \$ 8,322,961 | \$ 34,630,731 |
| Purchased Services | 11,518,964 | 3,517,599 | 15,036,563 |
| Supplies and Minor Equipment | 12,060,486 | 1,206,473 | 13,266,959 |
| Payroll Taxes and Benefits | 5,563,668 | 1,760,172 | 7,323,840 |
| Professional Fees | 3,090,744 | 20,166 | 3,110,910 |
| Depreciation | 1,322,846 | 540,317 | 1,863,163 |
| Leases and Rentals | 821,499 | 487,415 | 1,308,914 |
| Repairs and Maintenance | 1,071,306 | 571,942 | 1,643,248 |
| Other | 459,001 | 4,866,953 | 5,325,954 |
| Insurance | 2,095,943 | 561,962 | 2,657,905 |
| Telephone and Utilities | 58,431 | 538,654 | 597,085 |
| Travel, Meals, and Entertainment | 15,586 | 90,597 | 106,183 |
| Interest | - | 45,846 | 45,846 |
| Total | <u>\$ 64,386,244</u> | <u>\$ 22,531,057</u> | <u>\$ 86,917,301</u> |

| 2023 | Health Care Services | General and Administrative | Total |
|----------------------------------|-------------------------|-------------------------------|----------------------|
| Salaries and Wages | \$ 24,190,489 | \$ 7,474,326 | \$ 31,664,815 |
| Purchased Services | 14,309,735 | 4,544,999 | 18,854,734 |
| Supplies and Minor Equipment | 10,696,402 | 1,316,322 | 12,012,724 |
| Payroll Taxes and Benefits | 4,962,379 | 1,533,265 | 6,495,644 |
| Professional Fees | 3,090,773 | 12,856 | 3,103,629 |
| Depreciation | 1,478,193 | 603,769 | 2,081,962 |
| Leases and Rentals | 868,158 | 547,943 | 1,416,101 |
| Repairs and Maintenance | 986,216 | 396,469 | 1,382,685 |
| Other | 400,949 | 4,117,404 | 4,518,353 |
| Insurance | 1,927,276 | 238,455 | 2,165,731 |
| Telephone and Utilities | 62,519 | 602,132 | 664,651 |
| Travel, Meals, and Entertainment | 25,064 | 120,436 | 145,500 |
| Interest | - | 43,269 | 43,269 |
| Total | <u>\$ 62,998,153</u> | <u>\$ 21,551,645</u> | <u>\$ 84,549,798</u> |

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 12 LEASES

The Organization's operating leases primarily consist of real estate and equipment for various terms under long-term, noncancelable lease agreements. The Organization determines if an arrangement is a lease at contract inception. Operating and finance lease assets and liabilities are recognized based on the present value of the lease payments over the lease term at the commencement date. Because most of the Organization's leases do not provide an implicit rate of return, the Organization uses a risk-free rate based on the daily treasury yield curve at lease commencement in determining the present value of lease payments.

Most leases include one or more options to renew, with renewal terms that can extend the lease term for an additional month to another year. The exercise of such lease renewal options is at that Organization's sole discretion. For purposes of calculating lease liabilities, lease terms include options to extend or terminate the lease when it is reasonably certain that the Organization will exercise the option.

Leases with a term of 12 months or less at commencement are not recorded on the balance sheets. Lease expense for these arrangements is recognized on a straight-line basis over the lease term. The Organization paid \$652,947 and \$527,978 towards operating leases during fiscal years 2024 and 2023, respectively.

Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating lease expense for the year ending May 31, 2024 and 2023 was \$660,111 and \$527,978, respectively.

As of May 31, 2024 and 2023, the average remaining lease terms were 5.3 years and 6.4 years, respectively, and the average discount rate was 3.96% and 2.98%, respectively.

The following table summarized the maturity of the operating lease liabilities for the next five years as of May 31, 2024:

| <u>Fiscal Years Ending,</u> | <u>Amount</u> |
|-------------------------------------|---------------------|
| 2025 | \$ 752,622 |
| 2026 | 575,468 |
| 2027 | 569,085 |
| 2028 | 558,999 |
| 2029 | 330,109 |
| Thereafter | 387,500 |
| Total Operating Lease Payments | 3,173,783 |
| Less: Amounts Representing Interest | (303,999) |
| Total Operating Lease Liabilities | <u>\$ 2,869,784</u> |

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 13 COMMITMENTS AND CONTINGENCIES

Labor Agreements

At May 31, 2024, 92 of the Organization's 340 union-eligible employees were active under the collective bargaining agreements. At May 31, 2023, 94 out of the Organization's 306 union-eligible employees were active. Total employee count at year-end May 31, 2024 and 2023 was 526 and 482, respectively. The current collective bargaining agreement was renewed on June 1, 2021 through May 31, 2024, with wage renegotiations permissible in years two and three under the agreement. Subsequent to year end a new collective bargaining agreement was entered into through August 31, 2027.

Employee Health Insurance

The Organization maintains a stop-loss agreement with an insurance company to limit its losses on individual claims related to group employee insurance. Under the current terms of this agreement, the Organization's claims liability is limited to \$90,000 per employee per plan year. As of May 31, 2024 and 2023, the Organization accrued employee insurance claims of approximately \$300,000 and \$440,000, respectively, which are included in Accounts Payable in the accompanying consolidated balance sheets.

Stop-loss premiums and claims payments totaling \$3,909,343 and \$3,482,206 were expended during the years ended May 31, 2024 and 2023, respectively, and are included in Payroll Taxes and Benefits expense in the accompanying consolidated statements of operations.

Professional Liability Insurance

The Organization purchases medical malpractice insurance under a claims-made policy. Under such a policy, only claims made and reported to the insurer during the policy term, regardless when the incidents giving rise to the claims occurred, are covered. The Organization also purchases excess umbrella liability coverage, which provides additional coverage above the basic policy limits up to the amount specified in the umbrella policy.

Based upon the Organization's claims expense, an accrual has been made for the Organization's estimated medical malpractice costs, including costs associated with litigating or settling claims, under its malpractice insurance policy, amounting to approximately \$2,376,000 and \$2,006,000 as of May 31, 2024 and 2023, respectively. Professional liability reserve estimates represent the estimated cost of reported and unreported losses incurred through the respective consolidated balance sheet dates. The reserve for unpaid losses and loss expenses are estimated using individual case-basis valuations. Those estimates are subject to the effects of trends in loss severity and frequency. The estimates are continually reviewed and adjustments are recorded as experience develops or new information becomes known. The time period required to resolve these claims can vary depending upon whether the claim is settled or litigated. The estimation of the timing of payments beyond a year can vary significantly. Although considerable variability is inherent in professional liability reserve estimates, we believe the reserves for losses and loss expenses are adequate based on information currently known. It is reasonably possible that this estimate could change materially in the near term.

TAOS HEALTH SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2024 AND 2023

NOTE 13 COMMITMENTS AND CONTINGENCIES (CONTINUED)

Workers' Compensation Insurance

The Organization is insured under the New Mexico Hospital Workers' Compensation Group for purpose of providing insurance coverage for worker's compensation. The policy is a retrospectively rated policy whose premiums accrue based on the ultimate cost of the experience of a group of participating health care entities. The Organization expensed approximately \$255,000 and \$227,000 in workers' compensation premiums during 2024 and 2023, respectively. Such amounts are included in payroll taxes and benefits in the accompanying consolidated statements of operations.

Risk Management

The Organization is exposed to various risks of loss related to torts; theft of, damage to, and destruction of assets; errors and omissions, injuries to employees; and natural disasters. These risks are covered by commercial insurance purchased from independent third parties. This coverage has not changed significantly from the previous year.

Health Care Legislation and Regulation

The health care industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by health care providers. Violation of these laws and regulations could result in expulsion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed.

Management believes that the Organization is in substantial compliance with fraud and abuse as well as other applicable government laws and regulations. While no regulatory inquiries have been made, compliance with such laws and regulations is subject to government review and interpretation, as well as regulatory actions unknown or unasserted at this time.

Other

In the normal course of business, there could be various outstanding contingent liabilities such as, but not limited to, the following:

- Lawsuits alleging negligence in care
- Environmental pollution
- Violation of regulatory body's rules and regulations
- Violation of federal and/or state laws

No contingent liabilities such as, but not limited to those described above, are reflected in the accompanying consolidated financial statements. No such liabilities have been asserted and, therefore, no estimate of loss, if any, is determinable.



**INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER
FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS
BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN
ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS***

Board of Directors
Taos Health Systems, Inc.
Taos, New Mexico

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Taos Health Systems, Inc. (the Organization), which comprise the consolidated balance sheet as of May 31, 2024, and the related consolidated statements operations, net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 30, 2024.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Organization's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, we do not express an opinion on the effectiveness of the Organization's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's consolidated financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that were not identified. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that have not been identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Organization's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the result of that testing, and not to provide an opinion on the effectiveness of the Organization's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Organization's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



CliftonLarsonAllen LLP

Denver, Colorado
October 30, 2024



**INDEPENDENT AUDITORS' REPORT ON COMPLIANCE FOR EACH MAJOR
FEDERAL PROGRAM, REPORT ON INTERNAL CONTROL OVER
COMPLIANCE, AND REPORT ON THE SCHEDULE OF EXPENDITURES
OF FEDERAL AWARDS REQUIRED BY UNIFORM GUIDANCE**

Board of Directors
Taos Health Systems, Inc.
Taos, New Mexico

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Taos Health Systems, Inc.'s (the Organization) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Organization's major federal programs for the year ended May 31, 2024. The Organization's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Organization complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended May 31, 2024.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the *Auditors' Responsibilities for the Audit of Compliance* section of our report.

We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Organization's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Organization's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Organization's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Organization's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Organization's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as item 2024-001. Our opinion on each major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on the Organization's response to the noncompliance finding identified in our compliance audit described in the accompanying schedule of findings and questioned costs. The Organization's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance and therefore, material weaknesses or significant deficiencies may exist that were not identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be significant deficiencies.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiency in internal control over compliance described in the accompanying schedule of findings and questioned costs as item 2024-001 to be a significant deficiency.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on the Organization's response to the noncompliance finding identified in our compliance audit described in the accompanying schedule of findings and questioned costs. The Organization's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



CliftonLarsonAllen LLP

Denver, Colorado
October 30, 2024

**TAOS HEALTH SYSTEMS, INC.
SCHEDULE OF FINDINGS AND QUESTIONED COSTS
YEAR ENDED MAY 31, 2024**

Section I – Summary of Auditors’ Results

Financial Statements

1. Type of auditors’ report issued: Unmodified
2. Internal control over financial reporting:
- Material weakness(es) identified? _____ yes x no
 - Significant deficiency(ies) identified? _____ yes x none reported
3. Noncompliance material to financial statements noted? _____ yes x no

Federal Awards

1. Internal control over major federal programs:
- Material weakness(es) identified? _____ yes x no
 - Significant deficiency(ies) identified? x yes _____ none reported
2. Type of auditors’ report issued on compliance for major federal programs: Unmodified
3. Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? x yes _____ no

Identification of Major Federal Programs

| Assistance Listing Number(s) | Name of Federal Program or Cluster |
|-------------------------------------|--|
| 93.921 | Rural Health Care Services Outreach, Rural Health Network Development and Small Health Care Provider Quality Improvement |

Dollar threshold used to distinguish between Type A and Type B programs: \$ 750,000

Auditee qualified as low-risk auditee? _____ yes x no

TAOS HEALTH SYSTEMS, INC.
SCHEDULE OF FINDINGS AND QUESTIONED COSTS (CONTINUED)
YEAR ENDED MAY 31, 2024

Section II – Financial Statement Findings

Our audit did not disclose any matters required to be reported in accordance with *Government Auditing Standards*.

Section III – Findings and Questioned Costs – Major Federal Programs

2024 – 001 Procurement, Suspension & Debarment

Federal Agency: Health and Human Services
Federal program title: Rural Maternity and Obstetrics Management Strategies Program
Assistance Listing Number: 93.912
Federal Award Identification Number and Year: UK9RH33790-03 (9/1/22 – 8/31/23)
UK9RH33790-04 (9/1/23 - 8/31/24)

Pass Through Agency: None
Award Period: 9/1/2022 – 8/31/2023
9/1/2023 – 8/31/2024

Type of Finding:

- Significant Deficiency in Internal Control over Compliance and Other Matters

Criteria or specific requirement: 2 CFR Part 200 Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Award requires compliance with the provisions of procurement and suspension and debarment. The Organization should have internal controls designed to ensure compliance with these provisions.

Condition: During our testing over Procurement, Suspension & Debarment, we noted one instance where the Organization was unable to locate the procurement files to support the sole source justification for the procurement transaction along with not being able to locate documentation that the suspension and debarment check was performed prior to entering into a transaction with the vendor.

Questioned costs: None

Context: During our testing over Procurement, Suspension & Debarment, we noted one instance where the Organization was unable to locate the procurement files to support the sole source justification for the procurement transaction along with not being able to locate documentation that the suspension and debarment check was performed prior to entering into a transaction with the vendor.

Cause: The Organization lacks established internal controls and procedures over financial grant management. The Organization did not maintain files related to the procurement process and suspension and debarment checks.

Effect: Noncompliance results in possible Federal funds provided to ineligible vendors.

Repeat Finding: No.

TAOS HEALTH SYSTEMS, INC.
SCHEDULE OF FINDINGS AND QUESTIONED COSTS (CONTINUED)
YEAR ENDED MAY 31, 2024

2024 – 001 Procurement, Suspension & Debarment (Continued)

Recommendation: We recommend that the Organization create an internal policy over the documentation of sole source/non-competitive bid justification prior to contracting with a vendor using federal funds as well as implementing a process to ensure suspension and debarment checks are performed and documentation to show that the checks were performed are retained.

Views of responsible officials: The Chief Financial Officer (CFO) reviewed the procurement policy with the ROAMS Director. The CFO educated the ROAMS Director that the Organization will need to have a separate document on sole source justification and that a suspension and debarment check will need to be completed for every vendor used in either purchasing equipment or services. The CFO also sits on the governing board of the ROAMS program and will ensure the procurement policy is reminded when specific issues or approvals come to the governing board. The grant accountant will also give the CFO notice if equipment is being purchased or contracts entered into that are being paid out of federal grant funds and there is no attached separate documentation for sole source or documentation of check for suspension and disbarment.

TAOS HEALTH SYSTEMS, INC.
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
YEAR ENDED MAY 31, 2024

| Federal Grantor/Pass-Through Grantor/Program Title | Federal Assistance Listing Number | Agency/ Pass-Through Identifying Number | Federal Disbursements/ Expenditures |
|---|--|--|---|
| Department of Health and Human Services: | | | |
| *Rural Health Care Services Outreach, Rural Health Network Development and Small Health Care Provider Quality Improvement | 93.912 | UK9RH33790 | \$ 426,769 |
| Medical Assistance Program | 93.778 | MEP 20-2125 | <u>21,317</u> |
| Total Department of Health and Human Services Expenditures | | | 448,086 |
| Executive Office of the President | | | |
| High Intensity Drug Trafficking Areas Program | 95.001 | G21SN0024A | <u>348,524</u> |
| Total Expenditures of Federal Awards | | | <u>\$ 796,610</u> |

* Major Federal Program

TAOS HEALTH SYSTEMS, INC.
NOTE TO SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
MAY 31, 2024

NOTE 1 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS

This note is included to meet the requirements of 2 CFR Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) requirement that the schedule of expenditures of federal awards (the Schedule) include notes that describe the significant accounting policies used in preparing the Schedule. The accompanying Schedule includes the federal award activity of the Organization under programs of the federal government for the year ended May 31, 2024. The information in this Schedule is presented in accordance with the requirements of the *Uniform Guidance*. The Organization has elected to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance. Because the Schedule presents only a selected portion of the operations of the Organization, it is not intended to and does not present the financial position, changes in net assets, or cash flows of the Organization.



CLA (CliftonLarsonAllen LLP) is a network member of CLA Global. See CLAGlobal.com/disclaimer. Investment advisory services are offered through CliftonLarsonAllen Wealth Advisors, LLC, an SEC-registered investment advisor.